UCB News and Resources

UCB, the multinational biopharmaceutical company headquartered in Brussels, Belgium. and CDMO Samsung Biologics of South Korea have expanded their seven-year partnership with a new drug substance manufacturing deal worth 382 billion Korean won ($353 million).  The partnership involves Samsung Biologics manufacturing several